Campbell & CO Investment Adviser LLC Lowers Position in IQVIA Holdings Inc. $IQV

Campbell & CO Investment Adviser LLC decreased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 54.7% during the second quarter, according to its most recent filing with the SEC. The firm owned 1,597 shares of the medical research company’s stock after selling 1,926 shares during the period. Campbell & CO Investment Adviser LLC’s holdings in IQVIA were worth $252,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the business. Everpar Advisors LLC raised its stake in IQVIA by 4.6% in the second quarter. Everpar Advisors LLC now owns 1,404 shares of the medical research company’s stock worth $221,000 after buying an additional 62 shares in the last quarter. Private Trust Co. NA increased its holdings in shares of IQVIA by 12.5% in the 2nd quarter. Private Trust Co. NA now owns 603 shares of the medical research company’s stock valued at $95,000 after acquiring an additional 67 shares during the period. Independent Advisor Alliance lifted its stake in shares of IQVIA by 4.2% during the 1st quarter. Independent Advisor Alliance now owns 1,801 shares of the medical research company’s stock worth $318,000 after purchasing an additional 72 shares during the last quarter. Nemes Rush Group LLC boosted its position in IQVIA by 15.0% during the first quarter. Nemes Rush Group LLC now owns 621 shares of the medical research company’s stock valued at $109,000 after purchasing an additional 81 shares in the last quarter. Finally, Penserra Capital Management LLC grew its stake in IQVIA by 10.3% in the second quarter. Penserra Capital Management LLC now owns 963 shares of the medical research company’s stock valued at $151,000 after purchasing an additional 90 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Truist Financial restated a “buy” rating and issued a $265.00 price target (up from $235.00) on shares of IQVIA in a report on Wednesday, October 29th. TD Cowen downgraded shares of IQVIA from a “buy” rating to a “hold” rating and raised their target price for the company from $206.00 to $215.00 in a research note on Monday, November 3rd. UBS Group upped their price target on IQVIA from $225.00 to $250.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Weiss Ratings reissued a “hold (c)” rating on shares of IQVIA in a research report on Wednesday, October 8th. Finally, HSBC raised IQVIA from a “hold” rating to a “buy” rating and upped their target price for the company from $195.00 to $235.00 in a research report on Thursday, October 9th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $241.00.

Insider Buying and Selling

In other news, insider Eric Sherbet sold 4,000 shares of the company’s stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total value of $878,800.00. Following the sale, the insider directly owned 27,108 shares of the company’s stock, valued at $5,955,627.60. This represents a 12.86% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.60% of the company’s stock.

IQVIA Stock Performance

Shares of IQV opened at $216.24 on Tuesday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.70 and a current ratio of 0.70. The stock has a 50-day moving average of $203.29 and a two-hundred day moving average of $179.34. The stock has a market cap of $36.82 billion, a P/E ratio of 29.66, a P/E/G ratio of 2.48 and a beta of 1.34. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $228.12.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, beating analysts’ consensus estimates of $2.98 by $0.02. The business had revenue of $4.10 billion for the quarter, compared to analyst estimates of $4.07 billion. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The company’s revenue was up 5.2% on a year-over-year basis. During the same period in the prior year, the company earned $2.84 earnings per share. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. As a group, research analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.